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REVIEW
Abstract: Oral mucositis is a frequent and devastating side effect of anticancer treatments. It
impairs the patient’s quality of life and also can be life threatening because severe infections
and delayed or incomplete anticancer treatments may result. This problem has been largely
overlooked and underestimated in the past. However, recently studies have been performed
to precisely identify the epidemiology, cost, consequences, physiopathology, and treatments
of oral mucositis. Clinical guidelines have recently been published to help the daily
management of this frequent complication. In addition, some innovative new drugs, including
palifermin, have been developed to prevent and treat this major side effect of cancer treatments.
In this paper we summarize the recent developments of oral mucositis management.
Keywords: chemotherapy, radiotherapy, oral mucositis, palifermin
Introduction
Anticancer treatment-related mucosal damage to the oral cavity is referred to as oral
mucositis, and until recently it has been underestimated and overlooked (Wright et
al 2005). Treatments of this important side effect have likely been suboptimal and
based on assumptions rather than evidence. In addition, physiopathologic aspects
have not been addressed. Fortunately, this important issue has received greater
attention in recent years because oral mucositis not only has a dramatic impact on
the patient’s quality of life, but it also can adversely influence the administration of
an optimal antineoplasic treatment. Frequently, dose reductions, treatment delays, or
discontinuations are necessary to allow the oral lesions to heal. In addition, life-
threatening infections and higher treatment costs are clearly related to the severity of
oral mucositis. Additional days of total parenteral nutrition, use of narcotic analgesics,
total hospital charges, and 100-day mortality are also linked to the severity of mucositis
(Rubenstein et al 2004).
Important epidemiologic studies have been conducted in an attempt to isolate
risk factors and a great deal of basic research has advanced our understanding of the
mechanisms underlying oral mucositis. Taken together, these findings have provided
the basis for the development of new target therapies. Recently there have been
efforts to summarize knowledge acquired in the treatment of stomatitis. A critical
review of the literature allowed a panel of experts to propose clinical practice
guidelines for the prevention and treatment of this complication (Rubenstein et al
2004; Sonis et al 2004). This panel of experts from the Multinational Association of
Supportive Care and the International Society for Oral Oncology (MASSC/ISOO)
formed the Mucositis Study Section. In this paper, we will focus on anticancer-induced
oral mucositis, detailing the physiopathology and the treatment of this devastating
complication. We will particularly emphasize the emerging role of palifermin
(recombinant human keratinocyte growth factor), the first US Food and Drug
Administration (FDA)-approved target therapy for oral mucositis.
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Epidemiology
Cancer patients consider oral mucositis to be the most difficult
treatment-related toxicity to endure. The frequency of oral
mucositis is about 30% to 40% in the general cancer patient
population (Sonis 2004). However, patients receiving high-
dose chemotherapy (HDC) conditioning before hematopoietic
stem cell transplant (HSCT) have a 76% chance of developing
mucositis (Rao Naidu et al 2004). In addition, patients receiving
radiation, especially for head-and-neck cancers, have a 30%
to 60% chance of suffering from this complication. The
increased incidence is not only related to drugs used but also
to the number of chemotherapy cycles and the previous
occurrence of mucositis (Rao Naidu et al 2004). It is estimated
that annually there are approximately 400 000 cases of therapy-
induced oral mucositis (Rao Naidu et al 2004). Risk factors
can be divided into two main categories: risks related to patient
status and those related to the treatment itself.
Patient-related risks
Age has been shown to be a risk factor because children
experience more frequent and debilitating mucositis, probably
because of high cellular turnover. In addition, patients over 50
years of age may develop severe mucositis, perhaps because
of insufficient DNA repair (Balducci and Exterrman 2000).
Female patients are more likely to develop oral mucositis, for
instance after 5-fluorouracil (5-FU) treatment (Sonis 1998).
Nutritional status, type of malignancy, drug-induced xerostomia
(dry mouth), pre-existing mouth damage, and periodontal status
also play a role. Tobacco and alcohol consumption is probably
an important risk factor, although this remains controversial
(Dood et al 1999).
In addition, there has been a recent focus on genetic
predisposition for oral mucositis. Enzymatic phenotypes
probably play a key role in explaining the huge variation of
interindividual tolerance to anticancer treatment. For instance,
Ulrich et al (2001) reported that in patients undergoing HDC
for HSCT, a polymorphism in the 5, 10-methyl-
enetetrahydrofolate reductase gene was associated with a
differential rate of oral mucositis after treatment with
methotrexate. Finally, previous episodes of oral mucositis are
also an important risk factor.
Treatment-related risk
Mucositis is the second most frequent dose-limiting factor in
patients receiving chemotherapy (Peterson and Cariello 2004).
Chemotherapeutic drugs affecting DNA synthesis are
particularly stomatotoxic. For instance, 5-FU administration
is associated with oral mucositis in about 40% of patients
(Popescu et al 1999), and grade 3 to 4 oral mucositis is observed
in 10% to 15% of 5-FU recipients (MAC 1998). There is an
increased risk of mucositis with bolus and continuous infusions
compared with prolonged and repetitive low doses of
chemotherapeutic agents (Rao Naidu et al 2004). Other
cytotoxic agents are known to be very damaging to mucosa
(eg, alkylating agents such as anthracyclines and taxanes and
folate-based drugs such as methotrexate) (Sharma et al 2005;
Wright et al 2005). Finally, some drugs are excreted in the
saliva, such as methotrexate and etoposide (Rao Naidu et al
2004).
The dose of chemotherapy is also of great importance, as
illustrated by the 85%–95% incidence of mucositis in HSCT
recipients. Conditioning regimens including melphalan are
associated with high rates of oral mucositis (Wardley et al 2000).
In this setting, mucositis has been reported by patients as the
most distressing side effect they had to cope with (Bellm et al
2000). It is interesting to note that allogeneic transplant
recipients experience higher grades of mucositis compared with
those receiving autologous transplants (Wright et al 2005). In
addition, there is a strong relationship between low neutrophilic
count and the severity of stomatitis (Saadeh 2005).
Radiotherapy is also associated with an increased risk of
mucositis. The risk varies with dose, fractioning, and the site
of radiotherapy. In head-and-neck cancer patients, the incidence
of mucositis is over 50%, and this rate increases when
chemotherapy is given concomitantly or in HSCT recipients
when total body irradiation is administered (Trotti et al 2000;
Rubenstein et al 2004). Accelerated fraction even increases
the risk of mucositis to >70%, at which point mucositis is often
dose limiting (Trotti et al 2000). A summary of the different risk
factors is presented in Table 1.
The severity of mucositis has a direct influence on the
treatment planning with the necessity of dose reductions, delays,
or even discontinuations of anticancer therapy. This condition
also can favor the development of life-threatening infections,
especially if the patient is neutropenic. We recently reported
the case of a head-and-neck cancer patient with extensive
stomatitis who developed a Saccharomyces cerevisiae
fungemia infection during concomitant chemoradiotherapy
(Henry et al 2004).
Oral mucositis has important economic costs. In a recent
economic study, patients with mucositis had significantly higher
costs for nutrition/hydration support and prescription
medications but not for hospitalization compared with head-
and-neck cancer patients free of mucositis. This difference
resulted, however, in higher total costs for patients with
mucositis (Peterman et al 2001).Therapeutics and Clinical Risk Management 2006:2(2) 161
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Finally, it should be noted that there are huge discrepancies
in the way the severity of mucositis is described. Different scales
exist; the most commonly used are the National Cancer Institute
– Common Toxicity Criteria and the scale developed by the
World Health Organization (Sonis et al 2004). These scales
are graded from 0 to 4, and they are highly reproducible and
easy to use, combining evaluation of objective functions and
symptomatic variables. Grades III and IV are the most
debilitating states because patients are no longer able to eat or
require parenteral or enteral support. Other scales have been
developed, but they are essentially used for research purposes.
All of these methods of evaluation have been extensively
reviewed by Sonis et al (2004) and Peterson and Cariello
(2004). Recently, interesting pathologic evaluations also have
been described. These evaluations result in, for example,
estimates of the cell viability after mouthwashes using trypan
blue coloration (Wynenga et al 1999), measurement of
neutrophil levels in mouthwashes (Graham et al 1992), or
assessment of epithelial cell morphology, and differentiation/
maturation (Wynenga et al 1997). The use of these in vitro
pathological tests must be encouraged because they can reduce
the bias of subjective methodology.
Physiopathology
Clinically, oral mucositis appears about 7 to 10 days after the
start of chemotherapy. Recovery occurs between days 14 to
21 (Saadeh 2005). However, mucositis complicating
radiotherapy usually develops later, and it has a more chronic
course (Sonis et al 2004). It starts at a cumulative dose of 15
Grays (Gy) and peaks at 30 Gy. Despite this difference in timing
of occurrence, physiopathologic mechanisms underlying the
development of oral mucositis are probably identical, and these
mechanisms have recently been thoroughly explored. It has
become clear now that oral mucositis is not only the direct
consequence of a direct physical or chemical epithelial damage
but also the result of a cascade of events involving the entire
mucosa (Sonis 2004). Recently, Sonis and co-workers (2004)
proposed an interesting model that describes the different
biological events occurring during mucositis. In this model,
five different but interdependent phases have been identified,
as described below and depicted in a flow chart in Figure 1.
Initiation
Initiation is the first phase. Immediately after exposure to
radiotherapy or chemotherapy, there is DNA and non-DNA
damage. This damage is observed in mucosa and submucosa,
but only a small proportion of cells die quickly (Sonis 2004).
However, this initial insult triggers a cascade of biological
events. Generation of oxidative stress and reactive oxygen
species is thought to be the origin of injuries to mucosal cells,
tissues, and blood vessels.
Message generation
Message generation is the second phase. During this period,
there is an upregulation of transcription factors, such as nuclear
factor-κB (NF-κB), and genes coding for proinflammatory
cytokines (eg, tumor necrosis factor [TNF-α], and interleukins
[ILs] IL-1, IL2, and IL-6) and adhesion molecules. In addition,
enzymes such as neutral and acidic sphingomyelinases and
ceramide synthase are activated. This activation results in
apoptosis of submucosal endothelial cells and fibroblasts.
Fibroblast destruction leads to generation of fibronectin, which
Table 1 Proven and suspected risk factors for the development of mucositis
Risk factors for the development of mucositis
Patient-related risk factors Treatment-related risk factors
Age: Children and over 50 years old Chemotherapy: Type of drug
Dose and intensity
Induced neutropenia
Female sex Radiotherapy: Fractioning
Location
Combined with chemotherapy
Denutrition Bone marrow transplantation
Tumor location (eg, oral cavity, throat)
Drug-induced xerostomia
Pre-existing mouth damage
Periodontal status
Tobacco and alcohol consumption  
Genetic predispositionTherapeutics and Clinical Risk Management 2006:2(2) 162
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is responsible for a breakdown in connective tissue and the
release of metalloproteinases responsible for more apoptosis.
It should be noted that at this time the mucosa still seems
clinically normal.
Signaling and amplification
Signaling and amplification is the third phase. During this
period, the release of mediators from the initial injury amplifies
the destruction process through activation of positive feedback
loops, eg, TNF-α activates NF-κB (Sonis 2002) and
sphingomyelinase (Andriea-Abadic and Levade 2002), leading
to additional tissue destruction. It is interesting to note that in
fractionated radiotherapy, the insult is permanent and feedback
loops are constantly activated, blocking the healing process
(Sonis 2004).
Ulceration
Ulceration is the fourth phase. During this period mouth injuries
become clinically evident with areas of erosion. Erosions are
covered by fibrinous exudates that are also called
“pseudomembrane”. The exudate contains oral bacteria. This
period frequently coincides with the lowest neutrophil count.
Bacterial colonization of the submucosa is present and activates
macrophages, leading to new positive feedback and more
proinflammatory cytokine secretion. Other cytokines, such as
platelet-activating factor (PAF), may play an important role at
this stage. It seems that platelet aggregation may worsen oral
mucositis (Kuenen et al 2003). High salivary PAF levels are
correlated with mucositis severity (McManus et al 1993), and
pharmacologic inhibition of platelet aggregation results in
reduction of mucositis (Wang et al 2002). Finally, angiogenesis
is a late event of mucositis-induced ulcers.
Healing
Healing is the last phase. During this period, because of some
not yet well-characterized signals, epithelial cells directly
bordering the site migrate, proliferate, and differentiate. These
cells move beneath the pseudomembrane to reconstitute an
intact surface. This phenomenon is frequently concomitant with
the return of the white blood cell count to normal values. Cells
proliferate until the thickness of the mucosa is normal. However,
despite the fact that the mucosa appears to be clinically normal,
the environment has been altered and does not revert to its
original normal state. The patient is at risk of subsequent injury
with antineoplasic treatments.
Many unanswered questions remain concerning the
physiopathology of oral mucositis; for instance, the role of
PHASE I: INITIATION
DNA and non-DNA damages
Generation of oxidative stress and reactive oxygen species
PHASE II: MESSAGE GENERATION
Upregulation of transcription factors (NF-NB)
Increased production of IL-1, 2 and 6
Activation of acidic sphyngomyelinases and ceramide synthase
PHASE III: SIGNALING AND AMPLIFICATION
Positive feedback loops increase cytokine production
PHASE IV: ULCERATION
Clinically evident erosions
Bacterial colonization
Additional proinflammatory cytokine secretions
PHASE V: HEALING
Migration of epithelial cells covering ulcerations
Mucosa appears clinically normal
Figure 1 Flow chart of the different phases of mucositis development.Therapeutics and Clinical Risk Management 2006:2(2) 163
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saliva in the pathogenesis of oral injury is unclear. Saliva plays
a major role in oral homeostasis, notably through salivary
immunoglobulin A (Epstein et al 2002); however, surprisingly,
an attempt to increase production by pilocarpine hydrochloride
in cases of decreased or absent saliva (ie, xerostomia) failed to
moderate oral mucositis (Lockhart et al 2005).
Prevention and treatment of oral
mucositis
Many strategies exist to prevent and treat oral mucositis; most
of these are not generally accepted and are frequently based
on anecdotal reports or experiences. The lack of large, well-
designed randomized clinical studies adds to the confusion.
Recently a panel of experts reviewed the oral mucositis
literature and summarized the conclusions in clinical guidelines
(Rubenstein et al 2004; Sonis et al 2004). Fortunately, because
of a growing interest in this important side effect of cancer
treatment, interesting clinical studies have been reported, and
new drugs have been developed and tested.
Management of oral mucositis can be artificially divided
in three basic components: general oral care, prevention, and
palliative cares (Saadeh 2005).
General oral care
General oral care is the basis of oral mucositis management,
and it has a crucial role in prevention of its occurrence. The
aim is to reduce some host-related risk factors for stomatitis,
including lowering the impact of oral microbial flora. First a
pre-treatment oral assessment of the patient should be
performed. Comprehensive patient education plays a central
role, and a standard oral care protocol should be applied, but
there is not enough evidence to recommend one protocol over
another (Saadeh 2005). However, collective studies suggest
that the use of a systematic protocol improves patient outcome
(Rubenstein et al 2004). Some simple care should be suggested,
for instance: brushing teeth twice daily using a new toothbrush
at each chemotherapy cycle, daily flossing, and mouth rinsing
with sterile water after each brushing or flossing. In addition,
spicy food, alcoholic beverages, and alcohol-based
mouthwashes should be avoided (Larson et al 1998). Topical
antimicrobial treatments have frequently been shown to be
ineffective in modifying mucositis (Sonis 2004). For instance
use of amphotericin B, tobramycin, and polymyxin B has
shown efficacy in preventing oral mucositis induced by
radiotherapy but not by chemotherapy (Donnelly et al 2003).
This paradox can be explained in part by the physiopathology
of oral mucositis. These three compounds, in addition to their
anti-infective activity, also affect the production of pro-
inflammatory cytokines. Amphotericin B induces the
expression of genes coding for TNF-α and IL-1β (Rogers et al
1998) while both tobramycin and polymyxin B attenuate the
production and activity of these cytokines (Frieling et al 1997).
Prevention
Prevention is the second most important factor in addressing
oral mucositis.
Cryotherapy
Cryotherapy consists of the use of ice chips when bolus 5-FU
chemotherapy is administered. This cryotherapy induces a
temporary vasoconstriction, reducing blood flow and
chemotherapy delivery to oral mucosa (Saadeh 2005). This
procedure has been validated in two randomized clinical trials
(Maahood et al 1991; Cascinu et al 1994). The group receiving
cryotherapy experienced a reduction in mucositis of
approximately 50% (Maahood et al 1991). In practice, ice chips
are given for 30 minutes, starting 5 minutes before the beginning
of the chemotherapy. It should be noted that this procedure is
neither useful for continuous infusion of 5-FU nor for
methotrexate and anthracycline-containing therapies since the
half-life of these drugs is too long (Rubenstein et al 2004). The
advantages of this procedure are its simplicity, lack of toxicity,
and low cost.
Low level laser therapy
Low level laser therapy (LLLT) is also an important part of the
prevention strategies of mouth mucositis (Genot and Klastersky
2005). This procedure has been shown to be effective in patients
receiving HDC and HSCT (Barasch et al 1995; Cowen et al
1997). It promotes wound healing and reduces pain and
inflammation (Rubenstein et al 2004). In addition, LLLT
produces no toxicity and is nontraumatic to patients but requires
expensive materials and is time consuming.
Amifostine
Amifostine is a radioprotectant pro-drug that when
dephosphorylated protects normal but not malignant cells
against oxygen-based radicals, alkylator or organoplatinum
anticancer drugs (Spencer et al 2005), and radiotherapy. It acts
as a free-radical scavenger and has been shown to reduce pro-
inflammatory cytokine levels (Sonis 2004). The protection of
normal cells results in part from improved vascularity, higherTherapeutics and Clinical Risk Management 2006:2(2) 164
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alkaline phosphatase levels (required for dephosphorylation
of amifostine into its active metabolite WR-1065), and higher
pH of normal tissues (Spencer et al 2005). One randomized
trial has shown that amifostine reduced the incidence of
xerostomia, but not the severity of oral mucositis after
radiotherapy for head-and-neck cancers (Brizel et al 2000). A
recent randomized trial suggested that for ovarian cancer
patients, the frequency of severe grade III to IV carboplatin-
and paclitaxel-induced mucositis was reduced with amifostine
infusion (Lorusso et al 2003). The study by Spencer and
colleagues (2005) also suggested that amifostine reduced the
median grade of oral mucositis and the severity of mucositis,
but not the requirement of parenteral nutrition or analgesic use
after high-dose melphalan and HSCT for multiple myeloma.
Finally, amifostine reduced the frequency of severe esophagitis
after chemo-radiotherapy for non-small-cell lung cancer
(NSCLC) (Komaki et al 2002). Guidelines do not recommend
amifostine for prevention of oral mucositis except for NSCLC
patients undergoing concomitant chemo-radiotherapy
(Rubenstein et al 2004). One of the main issues with amifostine
administration is the toxicity. Nausea, vomiting, hypotension,
sneezing, flushing, somnolence, metallic taste, allergic
reactions, and hypocalcemia have been frequently reported.
However, subcutaneous injection could be more tolerable
(Bardet et al 2002).
Chlorhexidine
Chlorhexidine reduces mucosal colonization by
microorganisms, but this effect has never been translated into
clinical benefits for patients receiving either chemotherapy or
conventional or high-dose radiotherapy (Saadeh 2005). In a
randomized trial, chlorhexidine was found to be less effective
and more toxic than a placebo rinse in patients with head-and-
neck tumors receiving radiotherapy (Foote et al 1994).
Chlorhexidine is not recommended in the clinical guidelines
(Rubenstein et al 2004). In addition, chlorhexidine has several
side effects including inflammation, mouth discomfort, taste
alterations, and teeth staining (Pitten et al 2003).
Gelclair®
Gelclair
® was approved by the FDA in 2002 as a class 1 medical
device. It is a bioadherent gel that works by forming a coating
over mucosal lesions. Gelclair consists of polyvinylpyrrolidone,
hyaluronic acid, and glycerrhetinic acid. It is thought that this
molecule has anti-inflammatory properties. This preparation
is well tolerated and easy to use and has been shown to be
effective in reducing pain and oral discomfort in patients with
mucositis (Innocenti et al 2002).
Benzydamine
Benzydamine is a non-steroidal anti-inflammatory drug used
topically. It also has cytoprotective, anesthetic, and
antimicrobial properties (Wright et al 2005). This drug is
recommended by the MASCC/ISOO panel of experts for
prevention of radiotherapy-induced mucositis (Rubenstein et
al 2004). This product is safe, but its efficacy for prevention of
chemotherapy-induced mucositis is still unknown (Peterson
et al 2004).
Glutamine
Glutamine is a neutral amino acid rich in nitrogen that plays an
important role in mucosal cellular metabolism. In cancer
patients treated by chemotherapy or radiotherapy, a significant
glutamine depletion is frequently observed (Saadeh 2005).
Conflicting results have been published about the effect of
glutamine repletion in cancer patients. No positive effect was
reported for patients receiving 5-FU chemotherapy (Jebb et al
1994; Okuno et al 1999); however, two smaller studies
demonstrated a reduction in oral mucositis grade and duration
for patients who did not receive 5-FU (Skubitz and Anderson
1996; Anderson, Schroeder, et al 1998). The effect of glutamine
repletion in the BMT setting is also controversial with positive
(Anderson, Ramsay, et al 1998) and negative (Pytlik et al 2002)
studies.
AES-14 (SaforisTM)
AES-14 (Saforis
TM) by Aesgen Inc., Princeton, NJ, USA, is an
oral suspension delivering concentrated L-glutamine to the oral
mucosa through a proprietary vehicle. This system received a
fast-track approval from the FDA in January 2003 based on
studies showing a reduction of mucositis severity in BMT
patients and a shorter healing time after radiation (Elting et al
2004) compared with placebo. In addition AES-14 has a very
favorable toxicity profile.
Hematopoietic-growth factors
It has long been observed that mucositis often resolves within
days of granulocyte recovery. Some reports suggest that
granulocyte colony-stimulating factor (G-CSF) or granulocyte-
macrophage colony-stimulating factor (GM-CSF) can reduce
oral mucositis by accelerating neutrophil recovery (Wilkes
1998). However, randomized trials are controversial with
positive (Chi et al 1995; Kannan et al 1997) and negative resultsTherapeutics and Clinical Risk Management 2006:2(2) 165
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(Mascarin et al 1999; Makkonen et al 2000). There is currently
no evidence supporting use of G-CSF or GM-CSF
subcutaneously or in the form of mouthwash for patients with
oral mucositis (Karthaus et al 1998; Dazzi et al 2003). In
addition, these medications are very expensive.
Repifermin
Repifermin is the human keratinocyte growth factor 2 (KGF-
2). This substance has been studied in a phase II trial in which
patients received conditioning chemotherapy before autologous
HSCT. Repifermin significantly decreased the incidence of
grade 2 to 4 mucositis (Freytes et al 2004).
Palifermin
Palifermin is the recombinant keratinocyte growth factor 1
(rHuKGF-1). This molecule was purified from fibroblast
culture fluid in 1989 as a protein of 26–28kDa (Rubin et al
1989). Cloning showed that KGF and its receptor are members
of the fibroblast growth factor (FGF) family with 30%–45%
homology with other proteins of the FGF family (Finch et al
1989). It is also called FGF-7. Keratinocyte growth factor is
produced by fibroblasts and microvascular endothelial cells in
different organs like lungs, skin, stomach, and bladder
(MacDonald and Hill 2002). Keratinocyte growth factor
receptor expression has been found in gut epithelium,
hepatocytes, skin keratinocytes, alveolar type II cells, mammary
epithelium, and urothelium. Keratinocyte growth factor is also
a mediator of hair follicle growth and development (Oelmann
et al 2004). It can be considered as a mesenchymally-derived
paracrine mediator of epithelial growth and development
(MacDonald and Hill 2002).
Like other members of the FGF family, KGF is a heparin-
binding molecule and heparin is required for maximal KGF
stimulation through its receptor (Hsu et al 1999). When bound
to the receptor, KGF is internalized by endocytosis (MacDonald
and Hill 2002). Keratinocyte growth factor expression seems
mediated by pro-inflammatory cytokines like TNF-α, IL-1,
and IL-6 (Chedid et al 1994). Glucocorticoids appear to
decrease KGF production (impairing wound healing) while
estrogen and progesterone increase KGF in mammary gland
and endometrium (MacDonald and Hill 2002). Beneficial
effects of KGF on mucosa seem to be broader than expected.
For instance, KGF upregulates the transcription factor Nrf 2
that encodes genes playing a role in detoxifying radical oxygen
species (Braun et al 2002; auf dem Keller et al 2004),
attenuating TNF-α, and in the expression of adhesion molecules
(Just et al 2003).
One major concern about KGF is the presence of the
receptor on malignant cells from a variety of tissues (Oelmann
et al 2004). This finding has raised the possibility that
exogenous KGF might stimulate tumor cells. Interestingly,
some authors observed increased expression of the KGF/KGF
receptor in more-differentiated and less-advanced tumors, and
absence of expression in malignant versus benign cells or a
switch to FGF receptor isoforms with low binding affinity to
KGF (Oelmann et al 2004). In addition, KGF has been
described as stimulating matrix metalloproteinases and
inducing angiogenesis, mechanisms related to tumor
progression and metastatic potential. Fortunately, several
reports have shown that even if KGF modestly stimulated tumor
cell growth for a minority of solid tumor samples tested, it did
not impair tumor sensitivity to chemotherapy (Oelmann et al
2004) or radiotherapy (Hille et al 2003).
Pharmacokinetic variables of palifermin have been
determined in healthy volunteers and in metastatic colorectal
cancer patients (Neumann and Foote 2003). Palifermin has
been tested in clinical trials. In a phase I trial, Meropol
determined that KGF was well tolerated at doses up to 40 µg/
kg/day administered IV for 3 days before 5-FU plus leucovorin
in patients with advanced colon cancers (Meropol et al 2003).
This phase I study was randomized and suggested that patients
treated with palifermin had a lower rate of grade 2 to 4 mucositis
compared with patients who received placebo. It has been
shown recently in a large randomized trial that palifermin
reduced the incidence of grade 3 to 4 mucositis, decreased the
median duration of mucositis, the duration of opioid analgesic
use, and the incidence of use of parenteral nutrition in patients
with hematologic cancers receiving total-body irradiation and
HDC (Spielberger et al 2004). Adverse events encountered
were mild to moderate and transient and consisted mainly of
rash, pruritus, erythema, edema, hypoesthesia, paresthesia, and
mouth and tongue disorders like thickening and taste (Meropol
et al 2003). Asymptomatic and reversible increases of amylases
and lipases have also been observed (Sharma et al 2005).
In December 2004, palifermin was approved by the FDA
for prevention of mucositis in patients receiving HDC and
HSCT (Saadeh 2005). This molecule is the first innovative
“target-based” biologic agent for prevention of oral mucositis.
Many trials are currently ongoing to determine the efficacy of
this molecule in patients receiving radiotherapy, various
chemotherapy regimens, or an allogenic transplant. In animal
models, however, it has been shown that KGF can reduce acute
oral and intestinal mucositis after chemoradiotherapy orTherapeutics and Clinical Risk Management 2006:2(2) 166
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fractionated irradiation (Farell et al 1998; Dörr et al 2002).
Recently in allogeneic and haploidentical bone marrow
transplant animal models, KGF has shown interesting properties
in reducing the incidence of graft-versus-host disease (GvHD).
This effect seemed to be independent of repair of conditioning-
induced injuries (Panoskaltsis-Mortari, Taylor, et al 2000);
Vanclée et al 2005). In addition, it has been demonstrated that
KGF has a favorable effect on lung repair in mice after
allogeneic bone marrow transplant (Panoskaltsis-Mortari,
Ingbar, et al 2000). A recent clinical study reported 69 patients
who received palifermin after high-dose chemo-radiotherapy
and allogeneic bone marrow transplantation. This medication
was shown to be safe and well tolerated and did not have any
negative effects on engraftment, GvHD, and survival (Blazar
et al 2005). Another clinical study even suggested a survival
benefit in patients with a high risk for acute GvHD when
palifermin was added to tacrolimus and methotrexate (Reynolds
et al 2004).
Palliative cares
Palliative cares are implemented when mucositis is present.
Continuation of routine oral care should be advised (Wright et
al 2005). In addition, dietary guidelines should be respected
with avoidance of tobacco, alcohol, and spicy food. In some
cases, parenteral or enteral supports may even be required.
Finally, correct analgesia should be implemented. Morphine
has been recommended as the treatment of choice for patients
with mucositis undergoing HDC and HSCT (Rubenstein et al
2004). Prevailing clinical guidelines can help the clinician to
choose to best analgesia for the patient (WHO 1996). These
guidelines include the use of opioids, nonopioids, adjuvant
medications, and assessment tools. Topical anesthetics such as
viscous lidocaine are frequently used to decrease pain related
to oral mucositis; however, there are no experimental studies
to support this approach. In addition, viscous lidocaine requires
frequent applications and can be accompanied by burning
sensation and the blunting of taste (Saadeh 2005). A summary
of available therapeutic and prophylactic interventions is
presented in Table 2.
Conclusions
Oral mucositis is a frequent complication of anticancer
treatments that has long been overlooked and underreported.
The discrepancies between the different scales used to assess
the severity of mucositis add more confusion, and large
randomized clinical studies are scarce. Recently there has been
greater focus on the frequency, physiopathology, consequences,
and treatments of oral mucositis. These treatments remain
largely based on anecdotal reports and assumptions, but some
interesting studies have been done to provide evidence for these
approaches. The understanding of the physiopathological basis
of mucositis led to the development of target drug therapies, of
which palifermin is the hallmark. This new drug constitutes a
milestone in the management of cancer treatment-induced
toxicity. Other molecules are currently under investigation,
including transforming growth factor-β3, IL-11, and FGF-20
(Peterson and Cariello 2004).
The physiopathology of mucositis can also explain why
some preventive treatments like topical anti-infective agents
may have some paradoxical effects. Guidelines have recently
been developed to help clinicians in the daily management of
this devastating toxicity (Rubenstein et al 2004; Sonis et al
2004). One can not insist enough on the importance of
prevention, systematic oral care, and good patient information.
When oral mucositis is profuse, appropriate analgesia is
required. It is clear that treatment of mucositis is not based on
a unique and non-existent magic drug, but rather on a logical
and rational use of different modalities. Combining drugs in
specific sequences and at different times relative to the
administration of anticancer treatment will probably be the
solution for adequate management of oral mucositis. In the
near future, dose, timing, and sequencing of anti-mucositis
agents will probably be as well developed as chemotherapy
regimens (Peterson and Cariello 2004). It is interesting to note
that new drugs in development seem to have different
mechanisms of action. In addition, it is no longer pure optimism
to expect effective specific treatments of mucositis in the near
future (Sonis 2004).
Table 2 Candidate interventions for the management of oral
mucositis
Palliative
General oral care Prevention cares
Comprehensive patient Cryotherapy Continuation of
education routine oral cares
Standard oral care protocol Low-level laser Dietary guidelines:
therapy avoidance of
alcohol, tobacco,
spicy food
Brushing teeth twice daily Amifostine Enteral or
parenteral support
Daily flossing Gelclair
® Correct analgesia
Mouth rinsing with sterile Benzydamine
water
Avoidance of spicy food, AES-14
alcohol, tobacco
PaliferminTherapeutics and Clinical Risk Management 2006:2(2) 167
Oral mucositis and its treatments
References
Anderson PM, Schroeder G, Skubitz KM. 1998. Oral glutamine reduces the
duration and severity of stomatitis after cytotoxic cancer chemotherapy.
Cancer, 83:1433-9.
Anderson PM, Ramsay NK, Shu XO, et al. 1998. Effect of low-dose oral
glutamine on painful stomatitis during bone marrow transplantation. Bone
Marrow Transplant, 22:339-44.
Andriea-Abadic N, Levade T. 2002. Sphingomyelin hydrolysis during
apoptosis. Biochem Biophys Acta, 1585:126-34.
auf dem Keller U, Krampert M, Kümin A, et al. 2004 Keratinocyte growth
factor: effects on keratinocytes and mechanisms of action. Eur J Biol,
83:607-12.
Balducci L, Exterrman M. 2000. Management of cancer in the older person:
a practical approach. Oncologist, 20:224-37.
Barasch A, Peterson DE, Tanzer JM, et al. 1995. Heliun-neon laser effects on
conditioning-induced oral mucositis in bone marrow transplantation
patients. Cancer, 76:2550-6.
Bardet E, Martin L, Calais G, et al. 2002. Preliminary data of the GORTEC
2000-02 phase III trial comparing intravenous and subcutaneous
administration of amifostine for head and neck tumors treated by external
radiotherapy. Sem Oncol, 29(suppl 19):57-60.
Bellm LA, Epstein JB, Rose-Ped A, et al. 2000. Patients reports of
complications of bone marrow transplantation. Support Care Cancer,
8:33-9.
Blazar BR, Weisdorf DJ, DeFor TE, et al. 2005. Palifermin (A rHuKGF
molecule) is safe and well tolerated in patients (Pts) with hematologic
malignancies (HM) undergoing high-dose chemoradiotherapy (HD-CRT)
followed by allogeneic hematopoietic stem cell transplant (HSCT)
[abstract]. Biol Blood Marrow Transplant, 11(suppl 1):11.
Braun S, Hanselmann C, Gassman MG, et al. 2002. Nrf2 transcription factor:
a novel target of keratinocyte growth factor action regulates gene
expression and inflammation in the healing skin wound. Mol Cell Biol,
22:5492-505.
Brizel DM, Wasserman TH, Henke M, et al. 2000. Phase III randomised trial
of amifostine as a radioprotector in head and neck cancer. J Clin Oncol,
18:3339-45.
Cascinu S, Fedeli A, Fedeli SL, et al. 1994. Oral cooling (cryotherapy), an
effective treatment for the prevention of 5-fluorouracil-induced stomatatis.
Eur J Cancer B Oral Oncol, 30B:234-6.
Chedid M, Rubin JS, Csaky KG, et al. 1994. Regulation of keratinocyte growth
factor gene expression by interleukin 1. J Biol Chem, 269:10753-7.
Chi KH, Chen CH, Chan WK, et al. 1995. Effect of granulocyte-macrophage
colony-stimulating factor on oral mucositisin head and neck cancer
patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin
Oncol, 13:2620-8.
Cowen D, Tardieu C, Schubert M, et al. 1997. Low energy helium-neon laser
in the prevention of oral mucositis in patients undergoing bone marrow
transplan: results of a double blind randomised trial. Int J Radiot Oncol
Biol Phys, 38:697-703.
Dazzi C, Cariello A, Giovanis P, et al. 2003. Prophylaxis with GM-CSF
mouthwashes does not reduce frequency and duration of severe oral
mucositis in patients with solid tumors undergoing high-dose
chemotherapy with autologous peripheral blood stem cell transplantation
rescue: a double blind randomised, placebo-controlled study. Ann Oncol,
14:559-63.
Donnelly JP, Bellm LA, Epstein JB, et al. 2003. Antimicrobial therapy to
prevent or treat mucositis. Lancet Infect Dis, 3:405-12.
Dood MJ, Miaskowski C, Shiba GH, et al. 1999. Risk factors for
chemotherapy-induced oral mucositis: dental appliance, oral hygiene,
previous oral lesions, and a history of smoking. Cancer Invest, 17:278-
84.
Dörr W, Spekl K, Farell C. 2002. Amelioration of acute oral mucositis by
keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol
Biol Phys, 54:245-51.
Elting L, Peterson D, Sonis ST. 2004. Late-breaking information from the
2004 ASCO annual meeting. Oral Mucositis Newsletter, 1:1-12.
Epstein JB, Tsang AHF, Warkentin D, et al. 2002. The role of salivary function
in modulating chemotherapy-induced oropharyngeal mucositis: a review
of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod,
94:39-44.
Farell CL, Bready JV, Rex KL, et al. 1998. Keratinocyte Growth Factor protects
mice from chemotherapy and radiation-induced gastrointestinal injury
and mortality. Cancer Res, 58:933-9.
Finch PW, Rubin JS, Miki T, et al. 1989. Human KGF is FGF-related with
properties of a paracrine effector of epithelial cell growth. Science,
245:752-5.
Foote RL, Loprinzi CL, Frank AR et al. 1994. Randomized trial of
chlorhexidine mouthwash for alleviation of radiation induced-mucositis.
J Clin Oncol, 12:2630-3.
Freytes CO, Ratanathorn V, Taylor C, et al. 2004. Phase I/II randomised clinical
trial evaluating the safety and clinical effects of repifermin administered
to reduce mucositis in patients undergoing autologous hemotopoietic stem
cell transplantation. Clin Cancer Res, 10:8318-24.
Frieling JT, Mulder JA, Hendriks T, et al. 1997. Differential induction of pro-
and anti-inflammatory cytokines in whole blood by bacteria effects of
antibiotic treatment. Antimicrob Agents Chemother, 41:1439-43.
Genot MT, Klastersky J. 2005. Low level laser for prevention and therapy of
oral mucositis induced by chemotherapy and/or radiotherapy. Curr Opin
Oncol, 17:236-40.
Graham GJ, Ramenghi U, O’Connor MP, et al. 1992. Studies of oral neutrophil
levels in patients receiving G-CSF after autologous marrow
transplantation. Br J Haematol, 82:589-95.
Henry S, D’Hondt L, André M, et al. 2004. Saccharomyces Cerevisiae
fumgemia in a head and neck cancer patient: a case report and review of
the literature. Acta Clin Belg, 59:220-2.
Hille A, Rave-Frank M, Pradier O, et al. 2003. Effect of keratinocyte growth
factor on the proliferatio, clonogenic capacity and colony size of human
epithelial tumour cells in vitro. Int J Radiat Biol, 79:119-128.
Hsu YR, Nybo R, Sullivan JK, et al. 1999. Heparin is essential for a single
keratinocyte growth factor molecule to bind and form a complex with
two molecules of the extracellular domain of its receptor. Biochemistry,
38:2523-34.
Innocenti M, Moscatelli G, Lopez S. 2002. Efficacy of Gelclair in reducing
pain in palliative care patients with oral lesions: preliminary findings
from an open pilot study. J Pain Symptom Manage, 24:456-7.
Jebb SA, Osborne RJ, Maughan TS, et al. 1994. 5-fluorouracil and folinic
acid-induced mucositis: no effect of oral glutamine supplementation. Br
J Cancer, 70:732-5.
Just N, Tillie-Leblond I, Guery BP, et al. 2003. Keratinocyte growth factor
(KGF) decreases ICAM-1 and VCAM-1 cell expression on bronchial
epithelial cells. Clin Exp Immunol, 132:61-9.
Kannan V, Bapsy PP, Anantha N et al. 1997. Efficacy and safety of granulocyte-
macrophage colony-stimulating factor (GM-CSF) on the frequency and
severity of radiation mucositis in patients with head and neck carcinoma.
Int J Radiot Oncol Biol Phys, 37:1005-10.
Karthaus M, Rosenthal C, Huebner G, et al. 1998. Effect of topical oral G-
CSF on oral mucositis: a randomized placebo-controlled trial. Bone
Marrow Transplant, 22:781-5.
Komaki R, Lee JS, Kaplan B et al. 2002. Randomised phase III study of
chemoradiation with or without amifostine for patients with favourable
performance status inoperable stage II and III non-small cell lung cancer:
preliminary results. Semin Radiot Oncol, 12(suppl 1):46-9.
Kuenen BC, Levi M, Meijers JC, et al. 2003. Potential role of platelets in
endothelial damage during treatment with gemcitabine and the
angiogenesis inhibitor SU5416. J Clin Oncol, 21:2192-8.
Larson P, Miakowski C, MacPhail L, et al. 1998. The PRO-SELF mouth
aware program: an effective approach for reducing chemotherapy-induced
mucositis. Cancer Nurs, 21:263-8.Therapeutics and Clinical Risk Management 2006:2(2) 168
D’Hondt et al
Lockhart PB, Brennan MT, Kent ML, et al. 2005. Randomized controlled
trial of pilocarpine hydrochloride for the moderation of oral mucositis
during autologous blood stem cell transplantation. Bone Marrow
Transplant, 35:713-20.
Lorusso D, Ferrandina G, Greggi S, et al. 2003. Phase III multicenter
randomised trial of amifostine as cytoprotectant in first-line chemotherapy
in ovarian cancer patients. Ann Oncol, 14:1086-93.
MacDonald K, Hill G. 2002. Keratinocyte growth factor (KGF) in haematology
and oncology. Curr Pharm Des, 8:395-403.
Mahood DJ, Dose AM, Loprinzi CL, et al.1991. Inhibition of fluouracil-
induced stomatatis by oral cryotherapy. J Clin Oncol, 9:449-52.
Makkonen TA, Minn H, Jekunen A, et al. 2000. Granulocyte macrophage-
colony stimulating factor (GM-CSF) and sucralfate in prevention of
radiation-induced mucositis: a prospective randomised study. Int J Radiat
Oncol Biol Phys, 46:525-34.
Mascarin M, Franchin G, Minatel E, et al. 1999. The effect of granulocyte colony-
stimulating factor on oral mucositisin head and neck cancer patients treated
with hyperfractionated radiotherapy. Oral Oncol, 35:203-8.
McManus LM, Ostrom KK, Laer C, et al. 1993. Radiation-induced increased
platelet-activating factor activity in mixed saliva. Lab Invest, 68:118-24.
[MAC] Meta-Analysis Group in Cancer. 1998. Toxicity of fluorouracil in
patients with advanced colorectal cancer: effect of administration schedule
and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol,
16:3537-41.
Meropol NJ, Somer RA, Gutheil J, et al. 2003. Randomized phase I trial of
recombinant human keratinocyte growth factor plus chemotherapy:
potential role as mucosal protectant. J Clin Oncol, 21:1452-8.
Neumann TK, Foote MA. 2003. The development of supportive-care agents
for patients with cancer. Biotechn Ann Rev, 9:397-416.
Oelmann E, Haghu S, Kulimova E, et al. 2004. Influence of keratinocyte
growth factor on clonal growth of epithelial cells, lymphoma and
leukaemia cells and on sensitivity of tumor cells towards 5-fluorouracil
in vitro. Int J Oncol, 25:1001-12.
Okuno SH, Woodhouse CO, Loprinzi CL, et al. 1999. Phase III controlled
evaluation of glutamine for decreasing stomatitis in patients receiving
fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol, 22:258-61.
Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. 2000. Keratinocyte growth
factor facilitates alloengraftment and ameliorates graft-versus-host disease
in mice by a mechanism independent of repair of conditioning-induced
tissue injury. Blood, 96:4350-6.
Panoskaltsis-Mortari A, Ingbar DH, Jung P, et al. 2000. KGF pretreatment decreases
B7 and granzyme B expression and hastens repair in lungs of mice after
allogeneic BMT. Am J Physiol Lung Cell Mol Physiol, 278:988-99.
Peterman A, Cella D, Glandon G, et al. 2001. Mucositis in head and neck
cancer : economic and quality-of-life outcomes. J Natl Cancer Inst
Monogr, 29:45-51.
Peterson DE, Cariello A. 2004. Mucosal damage: a major risk factor for severe
complications after cytotoxic therapy. Sem Oncol, 31:35-44.
Peterson D, Beck S, Keefe D. 2004. Novel therapies. Sem Oncol Nursing,
20:53-8.
Pitten FA, Kiefer T, Buth C, et al. 2003. Do cancer patients with chemotherapy-
induced leukopenia benefit from an antiseptic chlorhexidine-based oral
rinse? A double-blind, block-randomised, controlled study. J Hosp Infect,
53:283-91.
Popescu RA, Norman A, Ross PJ, et al. 1999. Adjuvant or palliative
chemotherapy for colorectal cancerin patients 70 years or older. J Clin
Oncol, 17:2412-8.
Pytlik R, Benes P, Patorkova M et al. 2002. Standardized parenteral alanyl-
glutamine dipeptide supplementation is not beneficial in autologous
transplant patients: a randomised, double-blind placebo controlled study.
Bone Marrow Transplant, 30:953-61.
Rao Naidu MU, Venkat Ramana G, Usha Rani P, et al. 2004. Chemotherapy-
induced and/or radiation therapy-induced oral mucositis-complicating
the treatment of cancer. Neoplasia, 6:423-31.
Reynolds CM, Levine JE, Uberti JP, et al. 2004. Keratinocyte Growth Factor
(Palifermin) in combination with tacrolimus and methotrexate for the
prevention of acute graft-vs-host disease (aGvHD) in patients at high
risk of a GvHD [abstract]. Blood, 104:1228.
Rogers PD, Jenkins JK, Chapman SW, et al. 1998. Amphotericin B activation
of human genes encoding for cytokines. J Infect Dis, 178:1726-33.
Rubenstein EB, Peterson DE, Schubert M, et al. 2004. Clinical practice
guidelines for the prevention and treatment of cancer therapy-induced
oral and gastrointestinal mucositis. Cancer, 100:2026-46.
Rubin JS, Osada H, Finch PW, et al. 1989. Purification and characterization
of a newly identified growth factor specific for epithelial cells. Proc Natl
Acad Sci U S A, 86:802-6.
Saadeh CE. 2005. Chemotherapy and radiotherapy-induced oral mucositis: review
of perspective strategies and treatment. Pharmacotherapy, 25:540-54.
Sharma R, Tobin P, Clarke SJ. 2005. Management of chemotherapy-induced
nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol, 6:93-102.
Skubitz KM, Anderson PM. 1996. Oral glutamine to prevent chemotherapy
induced stomatatis: a pilot study. J Lab Clin Med, 127:223-8.
Sonis ST, Elting LS, Keefe D, et al. 2004. Perspectives on cancer therapy-
induced mucosal injury. Pathogenesis, measurement, epidemiology, and
consequences for patients. Cancer, 100:1995-2025.
Sonis ST. 2004. A biological approach to mucositis. J Support Oncol, 2:21-
36.
Sonis ST. 1998. Mucositis as a biologic process: a new hypothesis for the
development of chemotherapy-induced stomatotoxicity. Oral Oncol,
34:39-43.
Sonis ST. 2002. The biologic role for nuclear factor-kappaB in disease and its
potential involvement in mucosal injury associated with anti-neoplasic
therapy. Crit Rev Oral Biol Med, 13:380-9.
Spencer A, Horvath N, Gibson J, et al. 2005. Prospective randomised trial of
amifostine cytoprotection in myeloma patients undergoing high-dose
melphalan conditioned autologous stem cell transplantation. Bone Marrow
Transplant, 35:971-7.
Spielberger R, Stiff P, Bensinger W, et al. 2004. Palifermin for oral mucositis after
intensive therapy for hematologic cancers. N Engl J Med, 351:10-18.
Trotti A, Byhardt R, Stetz J, et al. 2000. Common toxicity criteria: version 2.0. An
improved reference for grading the acute effects of cancer treatment: impact
on radiotherapy. Int J Radiat Oncol Biol Phys, 47:13-47.
Ulrich CM, Yasui Y, Storb R, et al. 2001. Pharmacogenetics of methotrexate
toxicity among marrow transplantation patients varies with the
methylenetetrahydrofolate reductase C677T polymorphism. Blood,
98:231-4.
Vanclée A, Lutgens LC, Oving EB, et al. 2005. Keratinocyte growth factor
ameliorates acute graft-versus-host disease in a novel nonmyeloablative
haploidentical transplantation model. Bone Marrow Transplant, 36:907-15.
Wang J, Albertson CM, Zheng H, et al. 2002. Short-term inhibition of ADP-
induced platelet aggregation by clopidrogel ameliorates radiation-induced
toxicity in rat small intestine. Thromb Haemost, 87:122-8.
Wardley AM, Jayson GC, Swindell R, et al. 2000. Prospective evaluation of
oral mucositis in patients receiving myeloablative conditioning regimens
and hematopoietic progenitor rescue. Br J Haematol, 110:292-9.
Wilkes JD. 1998. Prevention and treatment of oral mucositis following cancer
chemotherapy. Sem Oncol, 25:538-51.
[WHO] World Health Organization. 1996. Cancer pain relief (2nd ed). Genova,
Italy: WHO
Wright J, Feld R, Knox J. 2005. Chemotherapy-induced oral mucositis: new
approaches to prevention and management. Exp Opin Drug Saf, 4:193-
200.
Wymenga AN, van der Graaf WT, Spijkervet FK, et al. 1997. A new in vitro
assay of quantitation of chemotherapy induced mucositis. Br J Cancer,
8:1062-6.
Wymenga AN, van der Graaf WT, Hofstra LS, et al. 1999. Phase I study of
transforming growth factor-beta 3 mouthwashes for prevention of
chemotherapy induced mucositis. Clin Cancer Res, 5:1363-8.